newsfilter
← Latest News
GlobeNewswire·

Sagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SGMT
  • Sagimet Biosciences Inc. granted an aggregate of 260,700 stock options to three newly hired employees on August 17, 2026.
  • The option awards were approved by the Compensation Committee of Sagimet's Board of Directors as inducement grants under Nasdaq Rule 5635(c)(4).
  • The exercise price for the options equals the closing price of Sagimet's Series A common stock on the grant date of August 17, 2026.
  • Each option carries a ten-year term with a vesting schedule of 25% on the one-year anniversary followed by monthly vesting over 36 months.
  • Vesting is subject to the continued service of each individual through the applicable vesting dates.
  • Sagimet is a clinical-stage biopharmaceutical company developing FASN inhibitors to target metabolic \& fibrotic pathways related to palmitate overproduction.